Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

Description

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.

Conditions

NSCLC Stage IV, NSCLC, Recurrent

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

Condition
NSCLC Stage IV
Intervention / Treatment

-

Contacts and Locations

Fairway

The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States, 66205

Kansas City

The University of Kansas Medical Center, Kansas City, Kansas, United States, 66160

Kansas City

The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States, 66205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Must have tumor tissue biopsy-proven to be NSCLC
  • * Must have a target lesion to evaluate treatment response
  • * Immunotherapy naïve metastatic/advanced/recurrent NSCLC patients
  • * Will receive single agent anti-PD-1/PD-L1 therapy (e.g. pembrolizumab, nivolumab, atezolizumab, avelumab or durvalumab, etc.). Patients can be on other interventional trial if they will be receiving single agent anti-PD-1/PD-L1
  • * Prior treatment with any forms of cancer immunotherapy
  • * Not competent to make medical decision, noncommunicative or noncompliant per treating physician's judgement
  • * Not English-speaking
  • * Patients that are pregnant
  • * Prisoners
  • * Students and employees
  • * Psychiatric illness/social situations that would limit compliance with study requirements

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jun Zhang, MD, PhD,

Jun Zhang, MD, PhD, PRINCIPAL_INVESTIGATOR, The University of Kansas Cancer Center

Study Record Dates

2024-12-31